Drug Approval | March 28, 2022
EU approves Evusheld to prevent Covid-19
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Registration is open for the global event that invites technology enthusiasts to bring innovative ideas to improve healthcare outcomes
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Vault PromoMats helps life sciences companies speed the creation, review, and distribution of compliant content. Built-in digital asset management enables content reuse and reduces spend on promotional materials
Recommendation is based on pivotal data from the phase III POLARIX study
Voluntary nationwide recall of lots of Accuretic (quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide tablets, and quinapril HCl/hydrochlorothiazide tablets due to n-nitroso- quinapril content
She joined Trivitron Healthcare in 1999 and has held several positions in the organisation
Sputnik Light is the first component of Sputnik V
The system boasts features that help streamline processes in the SPD and OR and reduce the possibility of wet sets.
Subscribe To Our Newsletter & Stay Updated
